Share

Pro Golfer Azahara Muñoz Shares Her Experience with Hashimoto’s Disease

Aza Photo 2 When professional golfer Azahara Muñoz started developing symptoms of Hashimoto’s thyroiditis – tiredness, cold extremities – she chalked them up to practicing too hard or traveling too much. It’s a stressful job. “You almost always have an excuse for it,” she says. But then around 2016, Muñoz noticed she began suffering from anxiety. Her hair...
Share

Higher Prevalence of Evening Chronotype in Women with PCOS Associated with Worse Metabolic Profile

A higher prevalence of the evening chronotype in women with polycystic ovary syndrome (PCOS) is associated with a worse hormonal and metabolic profile, according to a paper recently published in the Journal of Pineal Research. Researchers led by Giovanna Muscogiuri, MD, PhD, an assistant professor in the Unit of Endocrinology at Federico II University Medical...
Share

Mouse Model of Transgender Men Finds Active Testosterone Worsens IVF Outcomes

A study presented at ENDO 2022 in Atlanta this past summer suggests that active testosterone therapy for transgender men may negatively impact IVF outcomes. Research presented by Amanda Schwartz, MD, a reproductive endocrinology and infertility fellow at the University of Michigan, found that female mice currently receiving testosterone had fewer and less developed eggs retrieved....
Share

Study Links Diabetes and Worse Outcomes in Long-Term Survivors of Metastatic Breast Cancer

Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a study presented at ENDO 2022. The authors of the study point out that a well-established relationship between diabetes and breast cancer exists, but it’s still unclear how...
Share

Positive Clinical Data for Oral Treatment of Acromegaly Presented at ENDO

ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Share

New Report Highlights Reveal Future of Insulin Biosimilars

Last summer, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The FDA granted approval for insulin glargine-yfgn to Mylan Pharmaceuticals Inc., who is marketing the product as Semglee. Semglee...